Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

[1]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[2]  Chung-Pin Li,et al.  Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial , 2015, Oncotarget.

[3]  W. Scheithauer,et al.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. , 2015, Journal of the National Cancer Institute.

[4]  K. Chalkidou About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.

[5]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[6]  Chung-Pin Li,et al.  A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer , 2013, Cancer Chemotherapy and Pharmacology.

[7]  E. Basch,et al.  Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). , 2012, Journal of pain and symptom management.

[8]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[9]  R. Goldberg,et al.  Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Stauch,et al.  Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Thompson British National Formulary (BNF) , 2005 .

[14]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Walsh,et al.  Symptoms of pancreatic cancer. , 1991, Journal of pain and symptom management.

[16]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[17]  W. Scheithauer,et al.  Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Higginson International Agency for Research on Cancer. , 1968, WHO chronicle.